The Prescription Drug User Fee Act: Cause for Concern?

被引:2
|
作者
Gabay, Michael [1 ]
机构
[1] Univ Illinois, Chicago, IL USA
关键词
medication safety; legal aspects; ethics;
D O I
10.1177/0018578718757519
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The Prescription Drug User Fee Act (PDUFA) was originally enacted into law in 1992. PDUFA provides the Food and Drug Administration (FDA) with needed revenue in the form of various fees paid by drug and biologic manufacturers. The FDA utilizes this revenue to streamline the review and approval process for medications. Since the enactment of PDUFA, the median approval time for priority new drug applications and biologics license applications has reduced significantly. The FDA views PDUFA as a successful program that provides a consistent revenue stream to the agency, improves access to medications for patients, and allows industry to have a more predictable product review timeline. However, critics of PDUFA cite concerns including the potential for a lack of FDA independence and medication safety issues involving drugs approved after the existence of PDUFA.
引用
收藏
页码:88 / 89
页数:2
相关论文
共 50 条